Drug
Abilify Maintena
Abilify Maintena: highest development phase Post-Market, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| abilify maintena NCT03839251 | Post-Market | Schizophrenia |
Latest
No recent events.
Follow Abilify Maintena on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.